# RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

> **NCT06146101** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Incannex Healthcare Ltd** · enrollment: 560 (estimated)

## Conditions studied

- Obstructive Sleep Apnea

## Interventions

- **DRUG:** IHL-42X Low Dose
- **DRUG:** IHL-42X High Dose
- **DRUG:** Placebo
- **DRUG:** IHL-42X (Optimal Dose)
- **DRUG:** Dronabinol
- **DRUG:** Acetazolamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06146101
- **Lead sponsor:** Incannex Healthcare Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-02
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 560 (ESTIMATED)
- **Last updated:** 2025-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06146101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06146101, "RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06146101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*